ESPR - Esperion Therapeutic...

Valuation of Esperion Therapeutics, Inc.(ESPR), Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the

Esperion Therapeutics, Inc.

ESPR

NASDAQ

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

1.85 USD

-0.025 (-1.36%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

Valuation Date:

Apr 19, 2024 12:35 PM

Share Price on Valuation Date

$1.84

Stock Beta

0.822

Shares Outstanding

170418000

FMP

Home Terms of Service Privacy Policy Blog Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.